Intralipid for Amniotic Fluid Embolism (AFE)?

Joseph Eldor, Vladimir Kotlovker

Theoretical Medicine Institute, Jerusalem, Israel.

DOI: 10.4236/ojanes.2012.24029                

Abstract

In 1998 it was first showed that intravenous Intralipid could prevent or improve resuscitation from cardiovascular collapse by severe bupivacaine overdose in rats. Since then published examples now include toxicities related to verapamil, diltiazem, amlodipine, quetiapine and sertraline, haldoperidol, lamotrigine, olanzapine, propranolol, atenolol, nevibolol, doxepin, dosulepin, imipramine, amitriptyline, glyosphate herbicide, flecainide, venlafaxine, moxidectin, and others. Amniotic fluid embolism (AFE) is a rare but potentially catastrophic obstetric emergency. Despite earlier recognition and aggressive treatment, morbidity and mortality rates remain high. An estimated 5% - 15% of all maternal deaths in Western countries are due to AFE. The pathophysiology of AFE is not completely understood. AFE most commonly occurs during labor, delivery, or the immediate postpartum period. However, it has been reported to occur up to 48 h postpartum. Pulmonary hypertension and right heart strain/failure may be the result of physical amniotic fluid debris in the pulmonary vasculature or, perhaps more likely, result from circulating pulmonary vasoconstrictive mediators. Therapy with Intralipid in male rats resulted in 100% survival and prevented Pulmonary arterial hypertension-induced right ventricular failure by preserving right ventricular pressure and right ventricular ejection fraction and preventing right ventricular hypertrophy and lung remodeling. In preexisting severe Pulmonary arterial hypertension, Intralipid attenu-ated most lung and right ventricular abnormalities. The beneficial effects of Intralipid in Pulmonary arterial hypertension seem to result from the interplay of various factors, among which preservation and/or stimulation of angiogenesis, suppression and/or reversal of inflammation, fibrosis and hypertrophy, in both lung and right ventricular, appear to be major contributors. In conclusion, Intralipid not only prevents the development of Pulmonary arterial hypertension and right ventricular failure but also rescues preexisting severe Pulmonary arterial hypertension. Intralipid treatment is a new treatment for AFE (amniotic fluid embolism) which was never suggested before. Animal studies should be done in order to evaluate this new treatment modality.

Keywords

Intralipid; Bupivacaine Toxicity; Amniotic Fluid Embolism

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	G. L. Weinberg, T. VadeBoncouer, G. A. Ramaraju, M. F. Garcia-Amaro and M. J. Cwik, “Pretreatment or Resuscitation with a Lipid Infusion Shifts the Dose-Response to Bupivacaine-Induced Asystole in Rats,” Anesthesiology, Vol. 88, No. 4, 1998, pp. 1071-1075. doi:10.1097/00000542-199804000-00028
[2]	G. L. Weinberg, R. Ripper, P. Murphy, L. B. Edelman, W. Hoffman, G. Strichartz and D. L. Feinstein, “Lipid Infusion Accelerates Removal of Bupivacaine and Recovery from Bupivacaine Toxicity in the Isolated Rat Heart,” Regional Anesthesia and Pain Medicine, Vol. 31, No. 4, 2006, pp. 296-303.
[3]	G. Weinberg, R. Ripper, D. L. Feinstein and W. Hoffman, “Lipid Emulsion Infusion Rescues Dogs from Bupivacaine-Induced Cardiac Toxicity,” Regional Anesthesia and Pain Medicine, Vol. 28, No. 3, 2003, pp. 198-202.
[4]	C. Jamaty, B. Bailey, A. Larocque, E. Notebaert, K. Sanogo and J. M. Chauny, “Lipid Emulsions in the Treatment of Acute Poisoning: A Systematic Review of Human and Animal Studies,” Clinical Toxicology, Vol. 48, No. 1, 2010, pp. 1-27
[5]	M. S. Blaber, J. N. Khan, J. A. Brebner and R. McColm, “Lipid Rescue for Tricyclic Antidepressant Cardiotoxicity,” The Journal of Emergency Medicine, 2012, in press. doi:10.1016/j.jemermed.2011.09.010
[6]	D. French, C. Smollin, W. Ruan, A. Wong, K. Drasner and A. H. Wu, “Partition Constant and Volume of Distribution as Predictors of Clinical Efficacy of Lipid Rescue for Toxicological Emergencies,” Clinical Toxicology, Vol. 49, No. 9, 2011, pp. 801-809. doi:10.3109/15563650.2011.617308
[7]	J. X. Mazoit, “Cardiac Arrest and Local Anaesthetics,” La Presse Médicale, 2012, in press. doi:10.1016/j.lpm.2012.04.016
[8]	A. Papadopoulou, J. W. Willers, T. L. Samuels and D. R. Uncles, “The Use of Dye Surrogates to Illustrate Local Anesthetic Drug Sequestration by Lipid Emulsion: A Visual Demonstration of the Lipid Sink Effect,” Regional Anesthesia and Pain Medicine, Vol. 37, No. 2, 2012, pp. 183-187.
[9]	J. Mauch, O. M. Jurado, N. Spielmann, R. Bettschart-Wolfensberger and M. Weiss, “Resuscitation Strategies from Bupivacaine-Induced Cardiac Arrest,” Pediatric Anesthesia, Vol. 22, No. 2, 2012, pp. 124-129. doi:10.1111/j.1460-9592.2011.03688.x
[10]	J. Mauch, O. M. Jurado, N. Spielmann, R. Bettschart-Wolfensberger and M. Weiss, “Comparison of Epinephrine vs Lipid Rescue to Treat Severe Local Anesthetic Toxicity— An Experimental Study in Piglets,” Pediatric Anesthesia, Vol. 21, No. 11, 2011, pp. 1103-1108. doi:10.1111/j.1460-9592.2011.03652.x
[11]	V. Montiel, T. Gougnard and P. Hantson, “Diltiazem Poisoning Treated with Hyperinsulinemic Euglycemia Therapy and Intravenous Lipid Emulsion,” European Journal of Emergency Medicine, Vol. 18, No. 2, 2011, pp. 121-123. doi:10.1097/MEJ.0b013e32834130ab
[12]	P. Hamann, P. I. Dargan, N. Parbat, H. Ovaska and D. M. Wood, “Availability of and Use of Intralipid (Lipid Rescue Therapy, Lipid Emulsion) in England and Wales,” The Journal of Emergency Medicine, Vol. 27, No. 8, 2010, pp. 590-592. doi:10.1136/emj.2009.083352
[13]	P. L. West, N. J. McKeown and R. G. Hendrickson, “Iatrogenic Lipid Emulsion Overdose in a Case of Amlodipine Poisoning,” Clinical Toxicology, Vol. 48, No. 4, 2010, pp. 393-396. doi:10.3109/15563651003670843
[14]	D. B. Hiller, G. D. Gregorio, K. Kelly, R. Ripper, L. Edelman, R. Boumendjel, K. Drasner and G. L. Weinberg, “Safety of High Volume Lipid Emulsion Infusion: A First Approximation of LD50 in Rats,” Regional Anesthesia and Pain Medicine, Vol. 35, No. 2, 2010, pp. 140-144. doi:10.1097/AAP.0b013e3181c6f5aa
[15]	G. Cave and M. Harvey, “Intravenous Lipid Emulsion as Antidote beyond Local Anesthetic Toxicity: A Systematic Review,” Academic Emergency Medicine, Vol. 16, No. 9, 2009, pp. 815-824. doi:10.1111/j.1553-2712.2009.00499.x
[16]	M. Harvey and G. Cave, “Intralipid Outperforms Sodium Bicarbonate in a Rabbit Model of Clomipramine Toxicity,” Annals of Emergency Medicine, Vol. 49, No. 2, 2007, pp. 178-185doi:10.1016/j.annemergmed.2006.07.016
[17]	A. Conde-Agudelo and R. Romero, “Amniotic Fluid Embolism: An Evidence-Based Review,” American Journal of Obstetrics & Gynecology, Vol. 201, No. 5, 2009, p. 445. doi:10.1016/j.ajog.2009.04.052
[18]	M. S. Kramer, J. Rouleau, T. F. Baskett and K. S. Joseph, “Maternal Health Study Group of the Canadian Perinatal Surveillance System: Amniotic-Fluid Embolism and Medical Induction of Labour: A Retrospective, PopulationBased Cohort Study,” Lancet, Vol. 368, No. 9545, 2006, pp. 1444-1448doi:10.1016/S0140-6736(06)69607-4
[19]	H. A. Abenhaim, L. Azoulay, M. S. Kramer and L. Leduc, “Incidence and Risk Factors of Amniotic Fluid Embolisms: A Population-Based Study on 3 Million Births in the United States,” American Journal of Obstetrics & Gynecology, Vol. 199, No. 1, 2008, p. 49. doi:10.1016/j.ajog.2007.11.061
[20]	M. Knight, D. Tuffnell, P. Brocklehurst, P. Spark and J. J. Kurinczuk, “UK Obstetric Surveillance System: Incidence and Risk Factors for Amniotic-Fluid Embolism,” Obstetrics & Gynecology, Vol. 115, No. 5, 2010, pp. 910-917. doi:10.1097/AOG.0b013e3181d9f629
[21]	A. F. Gei, R. B. Vadhera and G. D Hankins, “Embolism during Pregnancy: Thrombus, Air, and Amniotic Fluid,” Anesthesiology Clinics of North America, Vol. 21, No. 1, 2003, pp. 165-182. doi:10.1016/S0889-8537(02)00052-4
[22]	J. R. Meyer, “Embolia Pulmonar Amnio Caseosa,” Brasil Medico, Vol. 2, 1926, pp. 301-303.
[23]	P. E. Steiner and C. C. Lushbaugh, “Maternal Pulmonary Embolism by Amniotic Fluid as a Cause of Obstetric Shock and Unexpected Deaths in Obstetrics,” Journal of the American Medical Association, Vol. 255, No. 16, 1986, pp. 2187-2203. doi:10.1001/jama.1986.03370160085032
[24]	A. Conde-Agudelo and R. Romero, “Amniotic Fluid Embolism: An Evidence-Based Review,” American Journal of Obstetrics & Gynecology, Vol. 201, No. 5, 2009, p. 445. doi:10.1016/j.ajog.2009.04.052
[25]	S. L. Clark, G. D. Hankins, D. A. Dudley, G. A. Dildy and T. F. Porter, “Amniotic Fluid Embolism: Analysis of the National Registry,” American Journal of Obstetrics & Gynecology, Vol. 172, No. 4, 1995, pp. 1158-1167.
[26]	A. O’Shea and S. Eappen, “Amniotic Fluid Embolism,” International Anesthesiology Clinics, Vol. 45, No. 1, 2007, pp. 17-28. doi:10.1097/AIA.0b013e31802b8853
[27]	R. D. Stanten, L. I. Iverson, T. M. Daugharty, S. M. Lovett, C. Terry and E. Blumenstock, “Amniotic Fluid Embolism Causing Catastrophic Pulmonary Vasoconstriction: Diagnosis by Transesophageal Echocardiogram and Treatment by Cardiopulmonary Bypass,” Obstetrics & Gynecology, Vol. 102, No. 3, 2003, pp. 496-498. doi:10.1016/S0029-7844(03)00161-3
[28]	C. F. James, N. G. Feinglass, D. M. Menke, S. F. Grinton and T. J. Papadimos, “Massive Amniotic Fluid Embolism: Diagnosis Aided by Emergency Transesophageal Echocardiography,” International Journal of Obstetric Anesthesia, Vol. 13, No. 4, 2004, pp. 279-283. doi:10.1016/j.ijoa.2004.03.008
[29]	S. Umar, R. D. Nadadur, J. Li, F. Maltese, P. Partownavid, A. van der Laarse and M. Eghbali, “Intralipid Prevents and Rescues Fatal Pulmonary Arterial Hypertension and Right Ventricular Failure in Rats,” Hypertension, Vol. 58, No. 3, 2011, pp. 512-518. doi:10.1161/HYPERTENSIONAHA.110.168781